High-flow therapy: physiological effects and clinical applications

Rebecca F. D'Cruz, Nicholas Hart, Georgios Kaltsakas

Source: Breathe, 16 (4) 200224; 10.1183/20734735.0224-2020
Journal Issue: December
Disease area: Respiratory critical care

Congress or journal article abstractFull text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Rebecca F. D'Cruz, Nicholas Hart, Georgios Kaltsakas. High-flow therapy: physiological effects and clinical applications. Breathe, 16 (4) 200224; 10.1183/20734735.0224-2020

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.

Related content which might interest you:
Update on novel anticoagulants: indications, dosing alternatives and outcomes
Source: International Congress 2018 – Pulmonary embolism: what we need to know
Year: 2018

Assessing the effect of medical therapy in COPD: from pathophysiology and biomarkers to clinical practice
Source: Annual Congress 2009 - PG15 The complexity of COPD: assessment and advanced therapies
Year: 2009

Clinical implications and novel therapies
Source: International Congress 2018 – Accelerated ageing in lungs
Year: 2018

Bronchodiator therapy in COPD: physiological effects
Source: Breathe 2008; 4: 342-344
Year: 2008

COPD mechanisms: novel aspects and implications for new therapies
Source: ERS Live 2007
Year: 2007

COVID-19 conundrum: clinical phenotyping based on pathophysiology as a promising approach to guide therapy in a novel illness
Source: Eur Respir J, 56 (2) 2002135; 10.1183/13993003.02135-2020
Year: 2020

Comparative efficacy of the therapy strategies for the asthma control maintenance in real clinical practice
Source: Annual Congress 2011 - Asthma: control and treatment
Year: 2011

Clinical implications and opportunities for new drug therapies
Source: Annual Congress 2008 - Deadly networks: disease-causing protein and DNA modifications
Year: 2008

A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials
Source: Eur Respir J 2015; 46: 243-249
Year: 2015

COVID-19 vaccines: immunology, regulation and clinical management
Source: Eur Respir Monogr 2021; 94: 244-260
Year: 2021

At the interface: the translational science supporting the clinical use of anti-cytokine therapy
Source: International Congress 2018 – New biologics for asthma: which patients, which agents, which results, at what cost?
Year: 2018

Our experience of 200 patients: Usage and maintenance of long-term oxygen therapy and non-invasive ventilation devices at home
Source: Annual Congress 2013 –Long-term NIV: COPD, sleep, obesity and outcomes
Year: 2013

Biologics: current use and future applications for personalised therapy
Source: Virtual Congress 2021 – Wheezing illnesses along the life span
Year: 2021

Novel paradigm for inhaled therapies: simulation of drug pharmacokinetic behaviour and effect of disease
Source: Eur Respir J 2003; 22: Suppl. 45, 474s
Year: 2003